Instylla
BEDFORD, MA · Biotechnology · 49 employees
Instylla is focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.
Funding history
- Venture - Series Unknown — $21.7M — Oct 2025
- Venture - Series Unknown — $30.3M — Nov 2023
- Venture - Series Unknown — $30.0M — Aug 2023
- Venture - Series Unknown — $30.3M — Oct 2020
Recent signals
- Oct 23, 2025: Raised $21.7M in Venture - Series Unknown
- Aug 05, 2025: Instylla, Inc. Appoints Sean Boyle as Chief Executive Officer
- Nov 03, 2023: Raised $30.3M in Venture - Series Unknown
- Aug 14, 2023: Raised $30.0M in Venture - Series Unknown
- Oct 15, 2020: Raised $30.3M in Venture - Series Unknown
See plans & pricing → Track Instylla’s funding, hiring, and signals — with verified contacts — on Fundz.